Contracepción sólo con gestágenos - Sociedad Española de ...
Contracepción sólo con gestágenos - Sociedad Española de ...
Contracepción sólo con gestágenos - Sociedad Española de ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
272<br />
SOCIEDAD ESPAÑOLA DE CONTRACEPCIÓN<br />
Korver T, Dieben T, Vree M, Edwards van Muijen A, Vromans L, San<strong>de</strong>n A van <strong>de</strong>r, Osta G van. A double-blind study comparing the<br />
<strong>con</strong>traceptive efficacy, acceptability and safety of two progestogen-only pills <strong>con</strong>taining <strong>de</strong>sogestrel 75 mcg/day or levonorgestrel<br />
30 mcg/day. Eur J Contracept Reprod Health Care 1998; 3:169-78.<br />
Korver T, Klipping, Heger-Mahn I, Duijkers I, Van Osta G. Maintenance of <strong>con</strong>sistent ovulation inhibition with the 75ug <strong>de</strong>sogestrelonly<br />
<strong>con</strong>traceptive pill Cerazette after scheduled 12-hour <strong>de</strong>lays in tablet-intake. Eur J Contracept Reprod Health Care 2004; 9:43.<br />
Kovalevsky G, Barnhart K. Norplant y otros anti<strong>con</strong>ceptivos implantables.Obstet Gynecol Clin North Am (ed esp) 2001; 1:85-92.<br />
(Nivel III).<br />
Landgren BM, Diczfalusy E. Hormonal effects of the 300 mcg norethisterone minipill. Contraception 1980; 21:87–113.<br />
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Man<strong>de</strong>l MG, et al. Oral Contraceptives and the Risk of Breast Cancer. N Engl J<br />
Med 2002 June; 346(26):2025-2032.<br />
Mascarenhas L. The insertion and removal of Implanon: practical <strong>con</strong>si<strong>de</strong>rations. Eur J Contracep Reprod Health Care. 2000:5: suppl<br />
2; 29-34.<br />
McCann MF and Potter LS. Progestin-only oral <strong>con</strong>traception: a comprehensive review. Contraception 1994; 50: S9-S195<br />
McCann MF, Moggia AV, Higgins JE, Potts M, Becker C. The effects of a progestins-only oral <strong>con</strong>traceptive (levonorgestrel 0.03 mg)<br />
on breast-feeding. Contraception 1989; 40:635-648.<br />
Moggia AV, Harris GS, Dunson TR, Díaz R, Moggia MS, Ferrer MA, et al. A comparative study of a progestin-only oral <strong>con</strong>traceptive<br />
versus non-hormonal methods in lactating women in Buenos Aires, Argentina. Contraception 1991; 44:31-43.<br />
Moghissi KS, Marks C. Effects of microdose progestogens on endogenous gonadotrophic and steroid hormones, cervical mucus<br />
properties, vaginal cytology and endometrium. Fertil Steril 1971; 22:424–34.<br />
Moghissi KS, Syner FN, McBri<strong>de</strong> LC. Contraceptive mechanism of microdose norethindrone. Obstet Gynecol 1973; 41:585–94.<br />
Organon Laboratories Limited. Implanon: Summary Product Characteristics (SPCs). http://www.medicines.org.uk. 2005.<br />
Organon Laboratories Limited. Implanon: Summary Product Characteristics (SPCs).<br />
Organon Laboratories Limited. Summary of Product Characteristics for <strong>de</strong>sogestrel-only pill (Cerazette). 1-6. 2004.<br />
Organon. Summary of Product Characteristics -Cerazette. 2003. http://www.medicines.org.uk<br />
Perheentupa A, Critchley HO, Illingworth PJ, McNeilly AS. Effect of progestin-only pill on pituitary-ovarian axis activity during lactation.<br />
Contraception 2003;67:467–71.<br />
Petitti DB, Piaggio G, Mehta S, Craviolo MC, Meirik O. Steroid hormone <strong>con</strong>traception and bone mineral <strong>de</strong>nsity: a cross sectional<br />
study in an international population. Obstet Gynecol 2000; 95:736-744 (Nivel II-3).<br />
Prapthardjo U, Wibowo S. The U technique: a new method for Norplant implant removal. Contraception. 1993:48:6;526-67<br />
Rice CF, Killick SR, Dieben TOM, Coelingh Bennick HJT. A comparison of the inhibition of ovulation achieved by <strong>de</strong>sogestrel 75<br />
microgrammes and levonorgestrel 30 microgrammes daily. Human Reproduction 1999;14:982-985.<br />
Rice CF, Killick SR, Hickling D, Coelingh Bennick HJT. Ovarian activity and vaginal bleeding patterns with a <strong>de</strong>sogestrelonly preparation<br />
at three different doses. Human Reproduction 1996;11:737-740.<br />
Sánchez Borrego R. Anti<strong>con</strong>cepción hormonal oral solo <strong>gestágenos</strong>: nuevas pautas. Cuad Med Reprod 2001; 7,2:53-64.<br />
Sánchez Borrego R, Gómez Martínez MA, Haya Palazuelo J, Martínez Benavi<strong>de</strong>s M, Martínez Santos F, Mattos Guillén I, Ruíz Reyna<br />
JM, por el Grupo CEMAH. Métodos anti<strong>con</strong>ceptivos <strong>con</strong> solo <strong>gestágenos</strong>. Revisión <strong>de</strong> <strong>con</strong>junto. Rev Iberoam Fertil 2002; 19,6:411-<br />
422.<br />
Sánchez Borrego R. Anti<strong>con</strong>cepción <strong>con</strong> <strong>sólo</strong> <strong>gestágenos</strong>: Particularida<strong>de</strong>s. En: Anti<strong>con</strong>cepción <strong>con</strong> <strong>sólo</strong> <strong>gestágenos</strong>. Revisión <strong>de</strong> los<br />
datos. Sánchez Borrego R, Lete Lasa I, eds. ERGON. Madrid, 2004. pp 3-16.<br />
Scherling Health Care Limited. Mirena: Summary Product Characteristics (SPCs). http://www.medcines.org.uk. 2001.<br />
Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral <strong>de</strong>nsity in women using <strong>de</strong>pot medroxyprogesterone acetate<br />
for <strong>con</strong>traception. Obstet Gynecol 1999; 93:233-238. (Nivel II-2).<br />
Sheth A, Jain U, Sharma S, Adatia A, Patankar S, Andolsek L, et al. A randomized, double-blind study of two combined and two<br />
progestogenonly oral <strong>con</strong>traceptives. Contraception 1982;25:243–52.
Change language